Gensight Biologics SA represents a strong set of values and a clear corporate philosophy. The company believes in delivering innovative gene therapies to patients suffering from severe retinal diseases. With a focus on precision medicine, Gensight Biologics SA aims to improve patients' lives by developing breakthrough treatments based on its unique Mitochondrial Targeting Sequence (MTS) technology. Guided by a patient-centric approach, the company's corporate philosophy revolves around scientific excellence, collaboration with key stakeholders, and a commitment to ethical conduct. Gensight Biologics SA's dedication to advancing gene therapies underscores its mission to address unmet medical needs and provide hope for patients worldwide.

Gensight Biologics SA is primarily present in several countries and regions. The company has a strong presence in Europe, particularly in France and the United Kingdom, where it has its main operations and headquarters. Gensight Biologics SA also operates in other European countries including Germany, Italy, Spain, and Switzerland. Additionally, the company has expanded its reach to the United States, establishing a presence in Cambridge, Massachusetts. With its focus on developing innovative therapies for severe genetic eye diseases, Gensight Biologics SA continues to expand its presence and collaborations globally.

Gensight Biologics SA has achieved several significant milestones. Firstly, the company successfully completed its IPO in 2016, raising a substantial amount of capital to fund its operations. Additionally, Gensight Biologics SA obtained breakthrough therapy designation from the U.S. FDA in 2017 for its lead product candidate, GS010. This designation highlights the potential of GS010 to address significant unmet medical needs. Furthermore, Gensight Biologics SA initiated Phase III trials for GS010, demonstrating its commitment to advancing innovative treatments for inherited retinal diseases. These milestones showcase Gensight Biologics SA's progress in both financial and clinical aspects, positioning it as a prominent player in the biotechnology industry.

Gensight Biologics SA is a leading biotechnology company specializing in developing innovative therapies to treat genetically driven ophthalmic diseases. Founded in 2012, Gensight Biologics has made significant breakthroughs in gene therapy and drug discovery, with a focus on inherited retinal diseases. The company's mission is to restore patients' vision and improve their quality of life through cutting-edge technology and scientific research. Gensight Biologics has collaborated with renowned medical institutions and academic partners globally, demonstrating its commitment to advancing the field of ophthalmology. With a strong track record of scientific achievements, Gensight Biologics continues to spearhead groundbreaking solutions for patients with vision-related disorders.

The main competitors of Gensight Biologics SA in the market include companies such as Spark Therapeutics, Inc., RegenxBio Inc., and MeiraGTx Holdings plc. These companies also operate in the field of gene therapy and aim to develop innovative treatments for various genetic diseases. By offering groundbreaking solutions and novel therapeutic approaches, Gensight Biologics SA competes with these companies to establish its presence in the market and provide effective treatments for patients with inherited retinal diseases.

Gensight Biologics SA is primarily active in the biotechnology and pharmaceutical industries.

The business model of Gensight Biologics SA involves developing and commercializing innovative gene therapies for ophthalmic diseases. As a biotechnology company, Gensight Biologics focuses on leveraging its expertise in gene therapy and ophthalmology to develop potential treatments for severe retinal diseases. By utilizing its proprietary technology platforms and extensive research, Gensight Biologics aims to provide therapeutic solutions that target the underlying causes of these vision impairments. Through strategic partnerships, clinical trials, and regulatory approvals, the company strives to bring its gene therapies to market, offering hope to patients with unmet medical needs in the ophthalmic field.

Gensight Biologics P/E suhe on −0,32.

Gensight Biologics KUV on 4,95.

AlleAktien kvaliteediskoor ettevõttele Gensight Biologics on 7/10.

oodatud Gensight Biologics käive on 3,61 mln. EUR.

oodatud Gensight Biologics kasum on −56,34 mln. EUR.

Gensight Biologics SA is a biopharmaceutical company specializing in the development of gene therapies for inherited retinal diseases. The company was founded in 2012 and is headquartered in Paris, France. They collaborate closely with leading scientists and research institutions and utilize advanced technologies to bring innovative gene therapies to the market. Gensight Biologics SA focuses on developing gene therapies for inherited retinal diseases, which are rare genetic conditions that can lead to blindness. They have three main products in their pipeline, namely GS010, GS030, and GS030-DP. GS010, their leading product, is used for the treatment of Leber's Hereditary Optic Neuropathy (LHON). It has already successfully passed Phase III trials and is currently in the process of obtaining market approval. GS030 and GS030-DP are intended for the treatment of Retinitis Pigmentosa. The business strategy of Gensight Biologics SA revolves around collaboration with partners to accelerate the development and commercialization of gene therapies. They work with leading scientists, research institutions, and pharmaceutical companies to advance gene therapy development. They have also formed a partnership with Sanofi to expedite the development of gene therapies for neurological disorders. Gensight Biologics SA has a broad product range and specializes in developing gene therapies for inherited retinal diseases. They have already conducted successful clinical studies for GS010 and are now in the phase of obtaining market approval. GS030 and GS030-DP are still in the development stage. The company is divided into three business segments: research and development, production, and clinical trials and market approval. In the research and development segment, Gensight Biologics SA focuses on the discovery and development of new gene therapies for inherited retinal diseases. They collaborate closely with leading scientists and research institutions to drive innovation in this field. In the production segment, Gensight Biologics SA develops and manufactures gene therapy products in compliance with Good Manufacturing Practice (GMP) standards. They have their own production facility in France and collaborate with other production partners to increase capacity for gene therapy production. In the clinical trials and market approval segment, Gensight Biologics SA develops strategies for conducting clinical trials and obtaining market approval for gene therapies for inherited retinal diseases. They work closely with regulatory authorities to obtain market approval for their products. Overall, Gensight Biologics SA has established itself as a leading company in the field of gene therapy for inherited retinal diseases. They utilize advanced technologies and techniques to bring innovative gene therapies to the market. They already have products in the pipeline in various stages of studies or development and are committed to expanding their product range in the future.

Gensight Biologics maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Gensight Biologics jaoks arvutada või ettevõte ei maksa dividende välja.

Gensight Biologics ISIN on FR0013183985.

Gensight Biologics WKN on A2ANGZ.

Gensight Biologics tähis on SIGHT.PA.

Viimase 12 kuu jooksul maksis Gensight Biologics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Gensight Biologics tõenäoliselt dividendi summas 0 EUR.

Gensight Biologics praegune dividenditootlus on .

Gensight Biologics maksab kvartaalset dividendi. See makstakse välja kuudel .

Gensight Biologics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Gensight Biologics on liigitatud sektorisse 'Tervis'.

Viimase Gensight Biologics dividendide saamiseks 2.12.2024 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 2.12.2024.

Viimane dividendimakse toimus 2.12.2024.

Aastal 2023 maksis Gensight Biologics 0 EUR dividende.

Gensight Biologics dividendid makstakse välja EUR.